https://doi.org/10.1007/s10147-021-02077-6
“Patients with peritoneal dissemination (PD) caused by abdominal malignancies are often associated with massive ascites, which shows extremely dismal prognosis because of the discontinuation of systemic chemotherapy mostly due to poor performance status. Many treatment methods, such as simple drainage, peritoneovenous shunting (PVS) and cell-free and concentrated reinfusion therapy (CART), have been used for symptom relief.
Peritoneal dissemination (PD) frequently occurs in recurrent abdominal malignancy, such as gastrointestinal and ovarian cancer. In addition to systemic chemotherapy, many treatment methods have been developed to improve the outcome of the patients with PD. However, treatment selection largely varies among countries and institutions as well as types of cancer, which may make it difficult to objectively evaluate their therapeutic efficacy. The treatment for PD from various primary tumors has been mentioned separately in guidelines of each cancer type. However, there are relatively few descriptions about PD. In particular, massive ascites is commonly associated with PD caused by various malignancies with extremely poor prognosis. However, no standard treatment strategy has been established for patients with malignant ascites. Therefore, it is meaningful to present therapeutic guidelines specific to PD form cross-organ perspective.”